Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad26.Mos4.HIV + CH505 TF chTrimer + ALFQ
- Development stage
- Unknown
- Lead developer
- U.S. Army Medical Research and Development Command
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Ad26.Mos4.HIV + CH505 TF chTrimer + ALFQ is an experimental HIV vaccine regimen designed to prevent HIV-1 infection. It is being developed by the U.S. Army Medical Research and Development Command (USAMRDC) in collaboration with Janssen Vaccines & Prevention B.V. and Duke University. The regimen utilizes a heterologous prime-boost strategy: Ad26.Mos4.HIV is a replication-incompetent adenovirus serotype 26 vector expressing mosaic HIV-1 antigens; CH505 TF chTrimer is a stabilized, soluble HIV-1 envelope (Env) protein trimer derived from a transmitted/founder virus; and ALFQ (Army Liposomal Formulation containing QS-21) is a potent adjuvant containing monophosphoryl lipid A (MPLA) and QS-21. The combination aims to induce both robust cellular immune responses and broadly neutralizing antibodies (bNAbs) against the HIV-1 envelope protein. It is currently being evaluated in the Phase I RV591 trial to compare standard versus rapid dose-escalating schedules.
- Other names
- Ad26.Mos4.HIV + CH505 TF chTrimer + ALFQ
02
Targets
gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on Ad26.Mos4.HIV + CH505 TF chTrimer + ALFQ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad26.Mos4.HIV + CH505 TF chTrimer + ALFQ.